Cabozantinib Amorphous Solid Dispersions for Variable Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cabozantinib formulations exhibit high variability in bioavailability and adverse effects due to pH-dependent solubility and food interactions, leading to inconsistent plasma levels and increased gastrointestinal toxicity.
Innovation Solution
Development of amorphous solid dispersions of cabozantinib with pharmaceutically acceptable carriers, such as HPMC-AS and PVP/VA copolymer, to enhance solubility and stability, allowing for reduced doses with consistent bioavailability and reduced gastrointestinal adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cabozantinib formulations (crystalline forms) are used, then manufacturing is simpler and cost is lower, but bioavailability is low and highly variable due to pH-dependent solubility
Solution Approach 1:
The patent transforms cabozantinib from crystalline to amorphous form, fundamentally changing the physical state parameter. This amorphous form is then incorporated into solid dispersion formulations with various carriers (polymers, lipids, surfactants), creating a range of formulations with different release profiles. This parameter change resolves the contradiction by dramatically improving bioavailability and reducing variability while maintaining manufacturability through established solid dispersion techniques.
Solution Approach 2:
The patent creates composite formulations by combining amorphous cabozantinib with various excipients including polymers (HPMC, Eudragit), lipids (lecithin, triglycerides), and surfactants. These composite materials provide both the solubility enhancement needed for improved bioavailability and the structural integrity required for manufacturable dosage forms, thus resolving the contradiction between reliability and complexity.
2Reliability
If higher doses of cabozantinib are administered to overcome low bioavailability, then therapeutic effect may be achieved, but gastrointestinal toxicity increases significantly
Solution Approach 1:
The patent introduces solubility-enhancing excipients as intermediaries between cabozantinib and the gastrointestinal environment. These excipients (polymers, lipids, surfactants) form complexes or dispersions that facilitate drug dissolution and absorption, allowing therapeutic doses to be achieved with lower actual cabozantinib content, thereby reducing gastrointestinal toxicity while maintaining therapeutic effect.
Solution Approach 2:
By changing the physical form from crystalline to amorphous and incorporating solubility-enhancing excipients, the patent alters the dissolution rate and absorption profile parameters. This enables achieving the same therapeutic effect at lower doses, thereby reducing the harmful gastrointestinal effects that increase with higher dosing.
3Reliability
If cabozantinib is administered with food to improve absorption, then bioavailability increases, but variability in pharmacokinetic parameters increases and dosing control becomes difficult
Solution Approach 1:
The patent designs formulations that are self-regulating in terms of drug release. The solid dispersion matrices and controlled-release excipients automatically regulate the dissolution and release of cabozantinib based on gastrointestinal conditions, eliminating the need for external control via food timing instructions. The formulation itself provides the consistency that would otherwise require strict dosing instructions.
Solution Approach 2:
The patent modifies the dissolution rate parameter through amorphous form conversion and excipient selection, creating formulations that maintain consistent drug release profiles regardless of food presence. This parameter change decouples bioavailability from food effects, allowing consistent dosing control without requiring strict fasting or feeding instructions.
4Reliability
If amorphous solid dispersions with multiple excipients are used, then bioavailability and stability are enhanced, but manufacturing complexity and production cost increase
Solution Approach 1:
The patent segments the formulation development into distinct categories based on excipient type (polymers, lipids, surfactants) and dosage form (tablets, capsules, granules). This segmentation allows manufacturers to select from standardized excipient classes and proven formulation platforms, reducing the complexity burden despite the advanced amorphous solid dispersion technology. Each segment has established manufacturing protocols that simplify production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersions provide enhanced bioavailability and reduced variability in pharmacokinetic parameters, enabling lower doses with equivalent therapeutic effects and minimizing gastrointestinal toxicity.
Implementation Method 1
Development of amorphous solid dispersions of cabozantinib with pharmaceutically acceptable carriers, such as HPMC-AS and PVP/VA copolymer, to enhance solubility and stability
Implementation Method 2
amorphous solid dispersions of cabozantinib with pharmaceutically acceptable carriers, such as HPMC-AS and PVP/VA copolymer, to enhance solubility and stability
Data Source
AI summary
Pharmaceutical compositions suitable for oral administration (such as a tablet or a capsule) are provided, which comprise a therapeutically effective amount of an amorphous solid dispersion of cabozantinib, e.g., for treating a proliferative disorder. Preferably, the amorphous solid dispersion consists of (a) cabozantinib or a pharmaceutically acceptable salt thereof (such as cabozantinib(S)-malate); (b) at least one pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof; (c) a pore-forming agent; and (d) a plasticizer.